AACR 2022: Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice

AACR 2022: Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice

Conclusions

  • We have generated a humanized mouse model expressing human VSIG4 in place of the murine counterpart.
  • mRNA and protein expression of human VSIG4 indicates successful generation of the humanized model.
  • Humanization of VSIG4 does not change the overall development, differentiation or distribution of immune cell types in spleen, lymph node and blood.
  • Anti-VSIG4 antibody treatment reduced tumor growth in B-VSIG4 mice, indicating that B-VSIG4 mice are a powerful model for evaluation of anti-human VSIG4 antibodies.

Related mouse model: B-hVSIG4 mice

Share:

    Please fill out the form below to request a download of this poster

    [posterfiledownload]